NCT00671424已完成1 期
An Evaluation of the Safety, Tolerability, and Pharmacodynamic Effects of GSK189075 When Administered With Furosemide or Hydrochlorothiazide
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 2
- 主要终点
- Serum sodium and potassium concentrations:
研究概览
简要总结
Many patients with type 2 diabetes also have conditions that are treated with diuretics. The patients may also be treated with GSK189075 for their diabetes. This study is planned to assess possible effects of administering GSK189075 in combination with two frequently used diuretics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •Male subjects who are between 18 and 50 years of age, inclusive.
- •BMI within the range 19-30 kg/m2 (inclusive).
- •Capable of providing signed and dated informed consent, which includes compliance with the requirements and restrictions listed in the consent form and with study-specific instructions provided by the site staff
排除标准
- •Significant renal disease as manifested by one or more of the following:
- •Symptoms of benign prostatic hyperplasia.
- •Prostate-specific antigen level of greater than 10ng/mL (or equivalent to moderately elevated per the local lab).
- •Any medical procedures requiring ingestion of radioactive agents within one week prior to dosing with study drug.
- •Cholecystectomy within 6 months before the first scheduled dose of study drug.
- •Any known or suspected gastrointestinal condition (or minor gastrointestinal surgery within 1 month prior to the first scheduled dose of study drug) that would likely interfere with the absorption or transit of study drug.
- •Any subject with either documented cirrhosis or history consistent with a diagnosis of cirrhosis.
- •History of gout.
- •History of sensitivity to any of the study medications, or their components, which in the opinion of the investigator or GSK Medical Monitor, contraindicates participation.
- •History of allergy to sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, loop diuretics (other than ethacrynic acid).
- •Subjects with clinical laboratory values outside ranges specified in protocol at screening or Day 1:
- •Significant ECG abnormalities at screening according to ranges specified in the protocol:
- •Systolic/Diastolic blood pressure: less than 80/60 mmHg or greater than 150/95 mmHg at screening.
- •Any clinically relevant abnormality identified on the screening physical or laboratory examination.
- •Hemoglobin or hematocrit below the reference range at screening
- •Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- •The subject has a positive drug/alcohol test at screening or check in into the clinic. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids, and benzodiazepines.
- •History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks/week for men or >7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits.
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months prior to screening.
- •A positive test for HIV antibody.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study (whichever is longer): 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56 day period.
- •History of sensitivity to heparin or heparin-induced thrombocytopenia.
- •History of sensitivity to latex
结局指标
主要结局
Serum sodium and potassium concentrations:
时间窗: baseline, Day 3, and Days 9-15
次要结局
- adverse events:(each visit)
- Physical Exam:(screening,Days -1,15,follow-up)
- ECG & vital signs:(Days -1,3,8,9,14,15,follow-up)
- Clinical labs:screening:(Days -1,3,8-15,follow-up)
- blood pressure:(days 7,13)
- urine labs:(Days 7,8,9,13,14)
- weight:(Days -1,3,4,9,10,15)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00871507Johnson & Johnson Pharmaceutical Research & Development, L.L.C.25
进行中（未招募）
4 期
DIALYSIS-TIR StudyEnd Stage Renal Disease on DialysisType 2 DiabetesNCT06042153University of Texas Southwestern Medical Center43
撤回
1 期
A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection TherapyDiabetes Mellitus, Type 2NCT02623465Eli Lilly and Company
已完成
1 期
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection TherapyDiabetes Mellitus, Type 2NCT02703337Eli Lilly and Company30
已完成
不适用
Type 2 Diabetes Mellitus: New Approaches to Optimize Medical Care in General PracticeType 2 Diabetes MellitusNCT00742547German Cancer Research Center204